Type 2 diabetes is characterized by insulin resistance, hyperglycemia, and progressive β cell dysfunction. Excess glucose and lipid impair β cell function in islet cell lines, cultured rodent and human islets, and in vivo rodent models. Here, we examined the mechanistic consequences of glucotoxic and lipotoxic conditions on human islets in vivo and developed and/or used 3 complementary models that allowed comparison of the effects of hyperglycemic and/or insulin-resistant metabolic stress conditions on human and mouse islets, which responded quite differently to these challenges. Hyperglycemia and/or insulin resistance impaired insulin secretion only from human islets in vivo. In human grafts, chronic insulin resistance decreased antioxidant enzyme expression and increased superoxide and amyloid formation. In human islet grafts, expression of transcription factors Nkx6.1 and MafB was decreased by chronic insulin resistance, but only MafB decreased under chronic hyperglycemia. Knockdown of Nkx6.1 or MafB expression in a human β cell line recapitulated the insulin secretion defect seen in vivo. Contrary to rodent islet studies, neither insulin resistance nor hyperglycemia led to human β cell proliferation or apoptosis. These results demonstrate profound differences in how excess glucose or lipid influence mouse and human insulin secretion and β cell activity and show that reduced expression of key islet-enriched transcription factors is an important mediator of glucotoxicity and lipotoxicity.
Stress-impaired transcription factor expression and insulin secretion in transplanted human islets

Chunhua Dai,1 Nora S. Kayton,2 Alena Shostak,1 Greg Poffenberger,1 Holly A. Cyphert,2 Radhika Aramandla,1 Courtney Thompson,1 Ioannis G. Papagiannis,1 Christopher Emfinger,1 Masakazu Shiota,2 John M. Stafford,1,2,3 Dale L. Greiner,4 Pedro L. Herrera,5 Leonard D. Shultz,6 Roland Stein,2 and Alvin C. Powers1,2,3

1Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, and 2Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 2VA Tennessee Valley Healthcare System, Nashville, Tennessee, USA. 3Department of Molecular Medicine, Diabetes Center of Excellence, University of Massachusetts Medical School, Worcester, Massachusetts, USA. 4University of Geneva, Faculty of Medicine, Department of Genetic Medicine and Development, Institute of Genetics and Genomics of Geneva and Centre Facultaire du Diabète, Geneva, Switzerland. 5The Jackson Laboratory, Bar Harbor, Maine, USA. 6The Jackson Laboratory, Bar Harbor, Maine, USA.

Type 2 diabetes is characterized by insulin resistance, hyperglycemia, and progressive β cell dysfunction. Excess glucose and lipid impair β cell function in islet cell lines, cultured rodent and human islets, and in vivo rodent models. Here, we examined the mechanistic consequences of glucotoxic and lipotoxic conditions on human islets in vivo and developed and/or used 3 complementary models that allowed comparison of the effects of hyperglycemic and/or insulin-resistant metabolic stress conditions on human and mouse islets, which responded quite differently to these challenges. Hyperglycemia and/or insulin resistance impaired insulin secretion only from human islets in vivo. In human grafts, chronic insulin resistance decreased antioxidant enzyme expression and increased superoxide and amyloid formation. In human islet grafts, expression of transcription factors NKX6.1 and MAFB was decreased by chronic insulin resistance, but only MAFB decreased under chronic hyperglycemia. Knockdown of NKX6.1 or MAFB expression in a human β cell line recapitulated the insulin secretion defect seen in vivo. Contrary to rodent islet studies, neither insulin resistance nor hyperglycemia led to human β cell proliferation or apoptosis. These results demonstrate profound differences in how excess glucose or lipid influence mouse and human insulin secretion and β cell activity and show that reduced expression of key islet-enriched transcription factors is an important mediator of glucotoxicity and lipotoxicity.

Introduction

Patients with type 2 diabetes (T2D) have impaired insulin secretion in response to glucose, and this β cell dysfunction is progressive, often requiring exogenous insulin therapy. Physiological levels of glucose and lipid stimulate insulin secretion. In excess, however, these nutrients are thought to directly impair insulin secretion and other aspects of β cell function and survival, a phenomenon often referred to as glucotoxicity, lipotoxicity, and glucolipotoxicity, indicating the pathological consequences of excess glucose and/or lipid (1–3). Glucotoxicity and lipotoxicity are widely regarded as important contributors to the progressive decline of β cell function in T2D.

Using rodent cell lines (4, 5), cultured rodent and human islets (6, 7), and in vivo rodent models (8, 9), investigators have suggested that excess glucose and/or lipid reduce insulin gene transcription (4), insulin protein content, glucose-stimulated insulin secretion (GSIS) (10, 11), and exocytotic events (5, 7). Use of somatostatin to “rest” β cells by halting insulin secretion does not reverse or prevent these effects, suggesting that these toxicities are not simply due to insulin depletion (12). Increased islet amyloid deposition, which is associated with β cell dysfunction and apoptosis in T2D patients (13, 14), is also a proposed consequence of excess glucose and/or lipid (15, 16). Such circumstances promote rodent β cell apoptosis (17, 18). Based on in vitro studies, the lipid contribution to apoptosis depends on the lipid species, with saturated fatty acids promoting apoptosis (19), potentially through ceramide formation (20, 21), altered lipid partitioning (22–24), or oxidative stress (2, 25–27).

Notably, high glucose and/or lipid levels reduce the expression and function of transcription factors critical to β cell development and function in cultured islets or in vivo rodent T2D models, particularly MAFA, NKX6.1, and PDX1 (13, 14, 28). In fact, transgenic misexpression of MAFA is able to partially rescue many islet β cell deficiencies in db/db mice, a model of T2D (29). Moreover, MAFA, MAFB, NKX6.1, and PDX1 were also selectively lost in human T2D islets (17, 18, 28); MAFA and MAFB are only coproduced in human islet β cells (30). Due to the relative sensitivity of these transcription factors to T2D stressors and their established role in regulating mouse islet cell function, it was proposed that MAFA and/or MAFB is compromised early and that overt changes in β cell dysfunction/death reflect subsequent loss of NKX6.1 and/or PDX1.

Mechanistic studies of human islets in vivo are difficult to perform. However, alternative approaches using islet cell lines and islets in culture do not mimic islet regulation in vivo. Although cultured islets contain some endothelial and nerve cells, they lack integrated, functional vascularization and innervation, which is...
reestablished upon transplantation (31). Moreover, culturing islets leads to changes in islet gene expression (32). Furthermore, such in vitro studies are challenged by selection of individual lipid species, lipid concentrations, and/or glucose concentrations. Rodent models of T2D, such as the ZDF rat or db/db mouse, also do not allow one to differentiate the effects of hyperglycemia from those of hyperlipidemia. In addition, it is possible that human islets have a unique response to these stress conditions in relation to mouse islets because there are fundamental differences in (for example) islet architecture (19, 33, 34), islet-cell transcription factor composition (20, 21, 35), and proliferative capacity (22–24).

As a result of these experimental limitations and species differences, the mechanisms of how excess glucose and/or lipid specifically impair human islet function in vivo are incompletely understood. To directly address if and how excess glucose and/or lipid levels differentially impair human versus mouse islet function, we generated or used models of metabolic stress in which engrafted human and mouse islets are exposed to hyperglycemia (i.e., glucotoxicity) and/or insulin resistance (i.e., characterized by excess lipid [lipotoxicity]) and examined the in vivo impact on insulin secretion, oxidative stress, transcription factor expression, the unfolded protein response (UPR), proliferation, apoptosis, and amyloid deposition.

Results

To examine the consequences of hyperglycemia and/or excess lipid on mammalian islets in vivo, we developed and characterized animal models involving transplanted human and/or mouse islets exposed to chronic hyperglycemia (NSG-DTR model), chronic insulin resistance (NSG-HFD), or acute hyperglycemia and acute insulin resistance (NSG-S961) (Figure 1, A and B). Each model capitalizes on the profound immunodeficiency of the NOD.Cg-Pkd1<sup>−/−</sup>NOD.IL2rg<sup>−/−</sup>/Sz (NSG) mouse background (36–39) to facilitate islet engraftment and employs preexperimental assessment of islet function to ensure islet quality (Figure 1C). Importantly, these models also allowed comparison of the in vivo response of human and mouse islets to these metabolic stresses.

**Chronic hyperglycemia model (NSG-DTR).** To directly examine the effect of chronic hyperglycemia on human islets in vivo, we developed a model in which one can specifically ablate native mouse pancreatic β cells without harming transplanted human islets, which engrafted under normoglycemic conditions. To ablate mouse β cells, we used the RIP-DTR mouse, in which human diphtheria toxin receptor (DTR) expression is controlled by the rat insulin promoter (RIP) (40). The RIP-DTR mouse was crossed onto the NSG background to produce the NSG-DTR<sup>+</sup> mice (Figure 1D). By electron microscopy, we observed normal fenestration of human vessels on chimeric vessels (31), we stained with PECAM to detect mouse cells (Supplemental Figure 8, A and B). By electron microscopy, we observed normal fenestration of human vessels on mouse islets because there are fundamental differences in (for example) islet architecture (19, 33, 34), islet-cell transcription factor composition (20, 21, 35), and proliferative capacity (22–24).

We determined that 4,000 islet equivalent (IEQ) maintained normoglycemia in the majority of NSG-DTR<sup>+</sup> mice (NSG-DTR mice with transplanted human islets) after DT-induced mouse β cell ablation, but that most mice with only 2,000 IEQ quickly became hyperglycemic and remained so (Figure 1D). Notably, mouse pancreatic insulin content was greatly reduced in both of the DT-treated groups, DT-HG and DT-NG (Figure 1E). Mice were grouped for subsequent analysis based on their observed glycemic status rather than by the number of islets transplanted. Thus, we use the terms DT-HG (hyperglycemia after DT), DT-NG (normoglycemia after DT), and PBS (animals given PBS instead of DT) to describe the human islet transplanted groups.

**Chronic insulin resistance model (NSG-HFD).** A high-fat diet (HFD) was used to introduce excess dietary lipid and induce insulin resistance on the NSG background. Some mice exhibited high sensitivity to the diet (HFD-HS), and others exhibited low sensitivity (HFD-LS), as defined by the change in body weight and fat mass, glucose tolerance, and serum insulin (Supplemental Figures 2 and 3). Body weight (Supplemental Figure 2, A and B), percentage of fat and lean mass (Supplemental Figure 2, C–F), glucose tolerance (Supplemental Figure 3, A–D), and fasting serum insulin (Supplemental Figure 3, E–H) were affected on both 45% and 60% HFDs. However, only mice on a 60% HFD were subsequently used to test the effects of insulin resistance on human islets in vivo. We also generated and characterized 2 widely used genetic models of insulin resistance on the NSG background: the Glut4<sup>−/−</sup> (NSG-Glut4) and the ob (NSG-ob/ob). The phenotypes of Glut4<sup>−/−</sup> and ob/ob mice on the NSG background (Supplemental Figures 5–7) differed considerably from those on the C57BL/6 background, so these models were not subsequently studied. These unexpected observations in the NSG-Glut4 and the NSG-ob/ob models exemplify how genetic background can affect the metabolic phenotype.

NSG mice with transplanted human islets were placed on the 60% HFD or regular diet (RD) (HFD+I and RD+I mice) for 12 weeks (Figure 1A), and this allowed a comparison of transplanted human islets and endogenous pancreatic mouse islets under the same metabolic conditions. One week before sacrifice (11 weeks on HFD), HFD+I mice had almost 3-fold greater weight gain (Figure 1F and Supplemental Figure 4A), twice the percentage of fat mass (Figure 1G), and reduced lean mass (Supplemental Figure 4B) compared with RD+I controls. In addition, HFD+I mice had higher serum triglyceride and cholesterol levels (Figure 1H), mild hyperglycemia (Figure 1I), and glucose intolerance (Figure 1J). HFD+I mice had dramatic hepatic lipid deposition (Supplemental Figure 4C), and mouse islet size and β cell mass were increased (Supplemental Figure 4, D and E), recapitulating prior studies on the effect of HFD on mouse islets (41–43).

We examined graft vessel morphology in human and mouse islet grafts in the NSG-HFD model to determine whether islet vascularization was affected by the HFD. Given that islet grafts revascularize with both donor and recipient endothelial cells, sometimes forming chimeric vessels (31), we stained with PECAM to detect mouse endothelial cells and with CD31, which identifies human endothelial cells. We found similar vessel morphology (size and density) in both diet groups, with human and mouse endothelial cells contributing to vessel formation (Supplemental Figure 8, A and B). By electron microscopy, we observed normal fenestration of human vessels on mouse islets.
Metabolic stresses impair stimulated human insulin secretion in vivo. DT-HG, HFD+I, and S961-treated mice all showed hyperglycemia (Figure 2, A, E, and J, respectively) and fasting human hyperinsulinemia (Figure 2, B, F, and K, respectively). Stimulated human insulin secretion dramatically decreased or was suppressed (DT-HG) in these groups (Figure 2, B, F, and K).

The ratio of stimulated human insulin to blood glucose, a measure of β cell responsiveness to hyperglycemia, was reduced in both DT-HG mice and HFD+I mice (Figure 2, C and G). In contrast, stimulated mouse insulin levels were quite elevated in HFD+I (Figure 2H) and unchanged in S961-treated mice (Figure 2L). This demonstrates a fundamental functional difference between mouse and human islets under identical metabolic stress conditions.

Insulin content of the human islet graft was unchanged in DT-HG and HFD+I mice (Figure 2, D and I), but it was markedly reduced in S961-treated mice (Figure 2M). In contrast, content both diets (Supplemental Figure 8, E and F). We found similar results in mouse islet grafts, with similar density, distribution, and size of vessels in both diet groups (Supplemental Figure 8, C, D, G, and H). Taken together, these data indicate that 12 weeks on HFD do not change the vasculature of transplanted human or mouse islet grafts.

Acute hyperglycemia and insulin-resistance model (NSG-S961).

To examine the effect of a shorter duration of metabolic stress on human islets, we treated mice with the insulin receptor antagonist S961 (Figure 1B), a 43-aa peptide antagonist known to induce many consequences of insulin resistance in rodents, including hyperglycemia, hyperinsulinemia, decreased hepatic glycogen storage, and decreased adipocyte triglyceride storage (44, 45). In our studies, S961-treated mice became hyperglycemic 24 hours after injection (Figure 1K) and remained so at 2 weeks (Supplemental Figure 9A). The insulin resistance of these mice is illustrated by extreme hyperinsulinemia of both human (Supplemental Figure 9B) and mouse insulin (Figure 1L).
similar affect on mouse insulin secretion. Insulin resistance promotes compensatory expansion of rodent β cell mass due to proliferation (42, 43, 46), and glucose has been reported to be a rodent and human β cell mitogen (47–49). As expected, native mouse pancreatic islets in HFD+I mice (Supplemental Figure 4, F and G) and NSG-S961 mice (Supplemental Figure 9, C and D) showed an increased percentage of Ki67+ β cells, reflecting induced proliferation. HFD+I mice also had larger islets and increased pancreatic β cell mass (Supplemental Figure 4, D and E). Human β cell proliferation was very low, and in stark contrast to mouse β cells, it was unchanged by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I). We use the term “proliferation” to refer to cells labeled by the condition of metabolic stress in each model (Figure 3, A–D, and I).
To address the possibility that the difference between human and mouse β cell proliferation in response to metabolic stress was related to the kidney capsule transplantation site, we transplanted NSG mice with mouse islets under the kidney capsule, prior to HFD or S961 treatment. Mouse graft β cell proliferation increased more than 6-fold in HFD-fed mice (Figure 3, E–G) and increased nearly 20-fold in NSG-S961 mice (Figure 3J), results that are similar to those seen in other studies using S961 (50, 51). Importantly, these results demonstrate that the profound difference in proliferation observed between human and mouse islets is species specific and not an effect of the transplantation site.

Neither chronic hyperglycemia nor insulin resistance causes human β cell apoptosis. Multiple in vitro studies have suggested that chronic metabolic stresses promote β cell apoptosis and decrease islet survival (17, 18). To address whether human β cell loss contributed to impaired stimulated insulin secretion, we measured expression of the key apoptosis genes BH3 interacting domain death agonist (BID), BCL2 associated agonist of cell death (BAD), and DNA damage inducible transcript 3 (DDIT3) (CHOP) in DT-HG and HFD+I human grafts. Two markers of apoptosis were decreased in DT-HG grafts (Figure 3K), and all 3 were unchanged in HFD+I grafts (Figure 3L). The lack of increased CHOP expression in both models indicates that human β cells under chronic hyperglycemia or chronic insulin resistance were not undergoing stress-induced apoptosis. Indeed, we observed only rare apoptotic β cells in both mouse and human grafts in the HFD model (Supplemental Figure 10, A–F) and in human grafts in the DTR model (Supplemental Figure 10G) at rates similar to those seen with control grafts. Thus, excess glucose or lipid does not lead to apoptosis in human or mouse islets in vivo.
Chronic hyperglycemia or chronic insulin resistance decreases antioxidant enzyme expression and increases superoxide levels in human islet grafts. Oxidative stress from increased levels of ROS is widely hypothesized as a cause of β cell dysfunction (2, 52). These cells are thought to be more sensitive to ROS due to their unusually low levels of antioxidant enzymes compared with other tissues (53, 54). We used these models to assess how oxidative stress responder gene products are affected by chronic in vivo hyperglycemia or insulin resistance.

Only the transcription factor nuclear factor, erythroid-derived 2-like 2 (NFE2L2) was reduced in DT-HG islet grafts in a panel of oxidative stress-related genes (Figure 4A). However, the antioxidant enzymes superoxide dismutase 1 and 2 (SOD1 and SOD2) and glutathione peroxidase 1 (GPX1), as well as NFE2L2, were decreased in HFD+I grafts (Figure 4B). Superoxide levels, as measured by dihydroethidium (DHE) staining, were higher in HFD+I grafts, but they were not changed in DT-HG grafts (Figure 4, C–E).

HFD+I mouse grafts showed no difference in superoxide levels (Figure 4F), indicating that the higher prevailing level of ROS induced by HFD is specific to human islets. These data demonstrate that changes in human islet antioxidant enzyme expression and subsequent increases in ROS are part of the response to chronic insulin resistance and may be a component of the lipotoxic functional consequences of these human grafts. Interestingly, the effect of hyperglycemia and insulin resistance on oxidative stress was different. The insulin resistance of the NSG-HFD model had a greater effect on both antioxidant enzyme expression and ROS levels, suggesting that oxidative stress may be more important as a lipotoxic mechanism than a glucotoxic mechanism.

UPR is not upregulated in response to chronic hyperglycemia or chronic insulin resistance. The efficacy of the UPR influences the ability of islets to meet increased insulin demand under metabolic stressors such as chronic hyperglycemia or insulin resistance.
To examine the UPR in human islets exposed to chronic hyperglycemia or insulin resistance, we measured the gene expression of 2 chaperones central to the UPR, HSPA5 (GPR78, BIP) and HSP90B1 (GRP94), as well as protein disulfide isomerase family A member 4 (PDIA4) (ERP72). HSPA5 and PDIA4 were increased in DT-NG grafts (Figure 4G), which successfully maintained normoglycemia, but were unchanged in both DT-HG and HFD+I grafts (Figure 4H), which had impaired insulin secretion. In contrast, pancreatic mouse islets of HFD+I mice, which had robust stimulated insulin secretion, had increased expression of all 3 UPR genes in response to HFD (Figure 4I).

These models demonstrate that islets with preserved stimulated insulin secretion, namely DT-NG human grafts and HFD+I mouse islets, upregulate components of the UPR in contrast with islets with impaired stimulated secretion, namely DT-HG human grafts and HFD+I human grafts. This suggests that inability to stimulate the UPR may be a glucotoxic and lipotoxic consequence. Alternatively, a lack of UPR induction could be a natural downstream response to either reduced or unchanged insulin transcription and/or translation, in which case this lack of UPR induction would reflect an appropriate homeostatic mechanism, rather than dysfunction. Importantly, mouse and human islets responded similarly.


Figure 5. Amyloid deposition in human islets is increased in NSG-HFD mice. (A) Relative mRNA level of IAPP in human grafts (n = 5/diet). *P < 0.05. (B) Representative images of amyloid in human grafts labeled with insulin (green) and thioflavin S (red). Original magnification, ×20. (C) Measurement of thioflavin S area of human grafts (n = 12 grafts/diet, **P < 0.01). Human, but not mouse, β cells accumulate intracellular lipid droplets. Electron microscopy images of β cells from human graft (D and E), mouse graft (F and G), and mouse pancreas (H and I). Arrows point to lipid droplet(s). N, nucleus, G, granule. Scale bar: 3 μm. (J–L) The number of lipid droplets per β cell in human grafts (β cell n = 45–70), mouse grafts (n = 50–71), and mouse pancreatic β cells (n = 56–74). *P < 0.05. Unpaired 2-tailed Student’s t test was used for analysis of statistical significance. Darker bars represent mouse data; lighter bars represent human data.
also had larger amyloid deposits than animals fed RD (Figure 5, B and C). In contrast, there was no change in IAPP expression, amyloid presence, or deposit size in the DT-HG grafts (Supplemental Figure 11). Due to the inherent inability of mouse IAPP to form amyloid (61), mouse grafts were not examined for amyloid. These data suggest that chronic insulin resistance, but not hyperglycemia, is the primary driver of amyloid deposition in human islets. However, this increased islet amyloid deposition did not cause human β cell apoptosis (Supplemental Figure 10F).

Human β cells exposed to chronic insulin resistance accumulate a greater number of intracellular lipid droplets. Studies have suggested that excess nutrients promote lipid droplet formation within islets (6) and that these lipid droplets affect β cell function (62). Using electron microscopy to examine intracellular lipid accumulation, we observed that human β cells (Figure 5, D, E, and J), but not mouse β cells (Figure 5, F–I, K, and L), extensively accumulated lipid droplets on RD. Lipid deposition in human β cells was also increased in response to HFD (Figure 5J). In addition, normal nontransplanted human pancreatic β cells contained lipid droplets (data not shown), suggesting that droplets were not a result of our manipulations. These data indicate that intracellular lipid accumulation is a feature of human, but not mouse, β cells and that HFD increases human β cell intracellular lipid accumulation.

Chronic insulin resistance and chronic hyperglycemia reduce NKX6.1 and/or MAFB in human β cells. Given the increased ROS in HFD+I human islet grafts, we postulated that those β cell–enriched transcription factors sensitive to this stressor, specifically MAFA, MAFB, NKX6.1, and/or PDX1, first shown to be affected in mouse models of diabetes and subsequently T2D islets, would be compromised under these circumstances (28, 63). MAFB, which is expressed in both human islet α and β cells (64), was reduced in both DT-HG human grafts (Figure 6A) and in HFD+I human grafts

**Figure 6.** MAFB and NKX6.1 transcription factors and downstream targets are reduced in human islets in DTR and HFD models. (A and B) mRNA levels of transcription factors in human grafts from NSG-DTR (A) or NSG-HFD (B) mice. *P < 0.05, **P < 0.01, DT-HG vs. PBS or NSG-HFD vs. NSG-RD (PBS, n = 5, DTR-NG, n = 5; DTR-HG, n = 10; RD+I, n = 5; HFD+I, n = 5). (C) Representative images of NKX6.1 protein in HFD+I and RD+I human grafts (left panels) and mouse grafts (right panels). Scale bar: 50 μm. (D and E) siRNA knockdown of NKX6.1 or MAFB in EndoC-βH1 cells. (D) Relative level of each gene after treatment with relevant siRNA. **P < 0.01, ***P < 0.001, relative to control (Ctrl) siRNA for each gene (n = 6/gene). (E) Static stimulation of insulin secretion with 5.5 mM or 15.5 mM glucose. **P < 0.01, relative to control siRNA (n = 3/group). (F and G) mRNA levels of downstream gene targets of MAFB and NKX6.1 in human grafts from NSG-DTR (F) and NSG-HFD (G) mice. *P < 0.05, **P < 0.01, DT-HG vs. PBS, or NSG-HFD vs. NSG-RD; †P < 0.05, DT-HG vs. DT-NG. Unpaired 2-tailed Student’s t test or 1-way ANOVA followed by Newman-Keuls multiple comparison test (A and F) was used for analysis of statistical significance. Blue represents the NSG-DTR model; red represents the NSG-HFD model. Darker bars represent mouse data; lighter bars represent human data.
(Figure 6B) as well as in mouse pancreatic islets in HFD+I mice (Supplemental Figure 12C). Because Mafb is not expressed in adult mouse islet β cells (65), this reduction of Mafb in mouse islets is most likely due to a decreased ratio of α to β cells, resulting from increased pancreatic β cell proliferation (Supplemental Figure 4, F and G). Gene expression and protein levels of NKX6.1, a transcription factor critical to β cell identity and function (66–68), were also decreased in HFD+I human grafts (Figure 6C), but were unchanged in mouse grafts and mouse pancreatic islets in the same mice (Figure 6C and Supplemental Figure 12D). This indicates that human NKX6.1 is more sensitive to HFD-induced insulin resistance than is mouse NKX6.1. Gene expression of MAFA, PDX1, and the pancreatic marker Pax6 was unchanged in DT-HG and HFD+I grafts (Figure 6, A and B, and Supplemental Figure 12, A and B), but mouse pancreatic islets in HFD+I mice had a dramatic increase in Mafa expression (Supplemental Figure 12C). Given the numerous genes regulated by Mafa and Nkx6.1 (66, 69, 70), these gene changes likely mediate the metabolic response in human and mouse islets.

Two MAFA and NKX6.1 targets, INS and GCK, were not changed in HFD+I human islets (Supplemental Figure 13A), but INS and Gck were increased in mouse islets from the same mice (Supplemental Figure 13C). INS expression was dramatically reduced in DT-HG grafts, compared with both PBS and DT-NG groups, but GCK expression was not (Supplemental Figure 13B). These data suggest that glucotoxic conditions reduce human insulin gene transcription. To ascertain whether decreased NKX6.1 or MAFB affect GSIS in human β cells, we performed knockdown experiments in the EndoC-β1H1 cell line (71). Reduction of either Mafb or NKX6.1 impaired GSIS (Figure 6, D and E), as observed for Mafb in prior studies (66, 72). The expression of various downstream targets of MAFA and NKX6.1 was measured to obtain insight into how changes in their levels could reduce GSIS. We found that SLC2A1 (GLUT1), SLC2A2 (GLUT2), and G6PC2 were significantly reduced in DT-HG human grafts (Figure 6F), whereas SLC2A2 (GLUT2), G6PD, AGT, and PRKAA1 were compromised in HFD+I grafts (Figure 6G). These data strongly suggest that the glucotoxic and lipotoxic changes in human islet function in vivo were at least partially mediated by reduction in the levels of NKX6.1 or MAFB transcription factors (Figure 7).

Discussion

The terms glucotoxicity, lipotoxicity, and glucolipotoxicity are used frequently to describe a paradigm wherein exposure to excess glucose, lipid, or both directly contribute to islet dysfunction and pathology (1–3). Based on studies in rodent β cell lines (4, 12, 73), human or rodent islets in vitro (7, 52, 63), and in vivo rodent models (8, 9, 28), a range of molecular mechanisms, including oxidative stress, ER stress, β cell apoptosis, and increased amyloid deposition (17, 18, 27, 74), have been proposed as contributing to these “toxicities.” However, there is limited information regarding whether these mechanisms are relevant to human islets in vivo. To address these gaps in our understanding, we generated and/or used mouse models of metabolic stress to study the effect of these conditions on human islets in vivo. These studies demonstrate that chronic and acute hyperglycemia and/or insulin resistance impair stimulated insulin secretion by human islets in vivo. This impairment is similar to observations in human T2D (75) and is not explained by β cell death or loss. Chronic insulin resistance decreased human islet antioxidant enzymes, increased superoxide, and decreased the key β cell transcription factors NKX6.1 and MAFB, while chronic hyperglycemia decreased MAFB, but not NKX6.1. Reducing either Nkx6.1 or Mafb in a human cell line impaired stimulated insulin secretion, mimicking the functional human islet defects seen in the in vivo models and indicating that reduction of these transcription factors is likely central to the observed defect. Insulin resistance and hyperglycemia potently stimulated mouse β cell proliferation, but not human β cell proliferation. In addition, HFD increased both islet amyloid and intracellular lipid deposits in human islets. Interestingly, the UPR was not increased in response to either condition, despite increased demand for insulin secretion. Importantly, these studies found that regulatory mechanisms noted in rodent models of T2D or in vitro studies of rodent or human islets were not operative in human islets challenged by chronic hyperglycemia or insulin resistance.

The presence of both human and mouse transplanted islets in the NSG-HFD and NSG-S961 models demonstrated fundamentally different responses of human islets to the same metabolic conditions. These differences included a lack of metabolic stress-induced β cell proliferation, decreased insulin gene expression, but unchanged insulin content, accumulation of intracellular lipid droplets, lack of UPR induction, the ROS superoxide in human islets (Figure 4D), and changes in transcription factor expression (Figure 6B). Previous studies have also demonstrated that basal human β cell proliferation rates are much lower than those in mouse (24, 76, 77), that compensatory increases in human β cell mass are far smaller than those achieved in mouse (78), and that human β cell transcription factor expression profiles are distinct from those in mouse and are not responsive to glucose (35). A recent study proposes that human β cell proliferation has been systematically underestimated in postmortem studies due to reduced Ki67 staining in postmortem tissues (79). However, the functional, vascularized state of the transplanted human islets in our studies argues against Ki67-related underestimation of human β cell proliferation. In addition, we observed these differences in human and mouse islets across multiple human islet donors. These results highlight the importance of studying human islets and assessing the translational relevance of mouse islet studies.
As a result of these findings, we propose a paradigm of direct and indirect effects of insulin resistance (excess lipid) and hyperglycemia (excess glucose) on human islets in vivo (Figure 7). In this paradigm, insulin resistance increases the level of ROS, which contributes to reduced expression of the transcription factors NKX6.1 and MAFB. This reduction in transcription factors then impairs stimulated insulin secretion. In this paradigm, hyperglycemia reduces expression of MAFB, which impairs stimulated insulin secretion. Other consequences of insulin resistance and/or hyperglycemia, namely increased islet amyloid formation, increased intracellular lipid droplets, and a lack of UPR stimulation, may contribute to and exacerbate this secretion deficit in the insulin resistance and hyperglycemia models.

In the NSG-HFD model of insulin resistance, the most highly reactive ROS, superoxide, is increased in HFD+I grafts. ROS have been proposed as the mechanism by which excess lipid and hyperglycemia exert many adverse cellular consequences (52, 80). ROS are important messengers required for insulin secretion (81, 82), but excess nutrients can elevate ROS levels and induce negative secondary consequences. Importantly, superoxide may work in conjunction with other ROS, such as hydrogen peroxide, to reduce NKX6.1 and MAFB expression. In response to excess lipid, the dominant site of lipid oxidation shifts from mitochondria to peroxisomes (26, 27). This shift is proposed to result in higher, toxic concentrations of hydrogen peroxide, against which insulin-producing cells have particularly low defenses (54, 83). Hydrogen peroxide can then directly reduce expression and/or protein function of NKX6.1, PDX1, and MAFA (28), defining a potential link between the excess lipid of insulin resistance and impaired stimulated insulin secretion. In our NSG-DTR model of chronic hyperglycemia, neither superoxide nor antioxidant expression changed in DT-HG grafts. MAFB, but not NKX6.1, expression is reduced in this model, suggesting that the type of metabolic stress may influence which transcription factors are affected. The focus of these studies was to examine chronic exposure to moderate, clinically relevant levels of hyperglycemia and insulin resistance. For this reason, analyses of ROS, amyloid, and gene expression were not performed in the S961 model, which shows acute exposure to extreme metabolic changes. It is possible, however, that these parameters are altered in response to S961 treatment.

Our knockdown experiments in EndoC-βH1 cells demonstrate that reduced NKX6.1 or MAFB expression leads to impaired human β cell activity (72). Not only is NKX6.1 fundamental to adult β cell identity and function (66–68), but knockdown of NKX6.1 in rat INS-1 cells and primary rat islets reduces stimulated insulin secretion without altering basal secretion or insulin content (68). This effect is similar to that seen in the NSG-HFD model, in which NKX6.1 expression is reduced. While human MAFB appears to be important to islet β cells (72), mouse MAFB is only essential to mouse islet cells (84). Our results suggest that impaired insulin secretion in HFD+I and DT-HG islets reflects reduced MAFB expression. Interestingly, neither PDX1 nor MAFA, both of which are reduced in human T2D islets (28), is reduced in HFD+I or DT-HG grafts, which may indicate that increased duration and/or severity of hyperglycemia and/or insulin resistance is required for loss of these particular factors.

In addition to oxidative stress, ER stress has been proposed as a mediator of gluco- and/or lipotoxicity. ER stress can be initiated by chronic activation of the UPR, which is critical for sustaining high levels of insulin production, processing, and packaging (85). Recent work has even suggested that the UPR is a sensor of insulin demand and a regulator of β cell mass (86). In our models of insulin resistance or hyperglycemia, the ability to increase stimulated insulin secretion correlates with increased UPR-related gene expression. Lack of UPR induction may functionally compromise the DT-HG and HFD+I human grafts. However, this lack of UPR induction could also be an appropriate response, in which the need for increased human insulin secretion, specifically, is tempered by the shared contribution to secreted insulin by the transplanted HFD+I human β cells and the pancreatic mouse β cells.

Beyond cellular stress responses, islet amyloid deposition, a pathologic hallmark of human T2D, has been suggested as a mechanism of β cell dysfunction and apoptosis (59, 87, 88). However, studying the development of amyloid in human islets is difficult. The majority of prior data comes either from autopsy studies that do not permit time-course studies or from mouse models that transgenically express human amyloid. Using our models, we found that HFD+I grafts had both more and larger amyloid deposits. Importantly, this increase in amyloid deposition did not lead to increased apoptosis, but could contribute to or reflect the impaired stimulated insulin secretion from human islets. Recent studies suggest that impaired autophagy increases susceptibility to amyloid-related toxicities (14, 89), a relationship that can now be examined in human islets using these models.

Our results indicate that β cell apoptosis does not contribute to impaired stimulated insulin secretion. Some prior studies demonstrating lipid- and glucose-induced β cell death used high concentrations of lipid or glucose in culture (17–20). Importantly, HFD likely generates very different lipid species than the selected lipid moieties of infusion or islet culture studies. Low levels of β cell apoptosis and a modest reduction in β cell mass are observed in human cadaveric T2D studies (90, 91). The duration of metabolic stress experienced by human patients (years or decades) may be required for β cell death to occur in vivo, or it may require the coexistence of hyperglycemia and insulin resistance that is present in those patients but not in our chronic models. Alternatively, the combination of very little apoptosis with a decrease in insulin content could point to β cell dedifferentiation in response to metabolic stress (92, 93), an intriguing possibility that requires further investigation.

Glucose has been proposed as a mouse β cell mitogen (47, 48). Both by infusing glucose into human islet graft-containing mice (94) and by using the hyperglycemia of the Akita mouse model (49), modest changes in human β cell proliferation rates were noted. However, in our models, hyperglycemia did not stimulate human β cell proliferation. Importantly, by cotransplanting mouse islets, we confirmed that mouse β cells under the kidney capsule proliferate in response to hyperglycemia or insulin resistance. The lack of increased human β cell proliferation in our models is consistent with human autopsy studies of lean, obese, pregnant, and diabetic patients (95, 96), although a caveat is that human β cells may not respond to in vivo murine stimuli. A previous study of transplanted human islets (97) also showed adaptation of endogenous islets to HFD-induced insulin resistance without
enhanced human β cell proliferation, leaving their observation of increased human graft volume and β cell percentage unexplained. The relative age of mouse and human islets must also be considered when interpreting results. Human islets used in our studies were from healthy, nondiabetic, adult donors in the age range in which humans develop T2D. Mouse islets were also from adults, but it is not clear how to control for islet age between these species. Although the NSG genetic background is critical for successful islet engraftment, it also eliminates many islet-immune interactions, which may affect islet function and health (98–100).

This work demonstrates that hyperglycemia and insulin resistance impair stimulated insulin secretion in human islets in vivo and this is at least partly due to reduced expression of NKX6.1 and/or MAFB. In addition, insulin resistance has a broader set of negative consequences than hyperglycemia. Surprisingly, neither hyperglycemia nor insulin resistance stimulated β cell proliferation or apoptosis, and the responses of human and mouse islets were fundamentally different in many aspects. Future studies should focus on determining how these abnormalities relate to the clinical phenotypic and genetic subgroups of T2D (101), contribute to the decline in insulin secretion in T2D, and can be therapeutically addressed.

Methods

Insulin-resistant animal models on an immunodeficient background. Adult male and female (The Jackson Laboratory) B6.Cg-Prkdc scid/Scid LEPRob mice were mated with NSG mice (25), and the LEPRob mutation (abbreviated as ob) was subsequently backcrossed for 10 generations to the NSG strain to create the NSG-ob strain. The colony was maintained by intercrossing NSG +/+ob heterozygotes. These crosses produced NSG-ob/ob mice as well as NSG +/+ob and +/+ WT controls. NSG-ob/ob and NSG-WT controls were studied at 3, 6, and 11 weeks of age. (B6;129 Sv)-Glut4+/+ mice were mated with NSG mice and the Glut4 mutation was subsequently backcrossed for 10 generations to the NSG strain to create the NSG-Glut4 strain. The colony was maintained by intercrossing NSG +/-Glut4 heterozygotes. These crosses produced NSG-Glut4+/+ mice as well as NSG-Glut4+/− and Glut4−/− WT controls. To create diet-induced, insulin-resistant mice on the immunodeficient background, we fed NSG mice with RD or HFD. Two HFDs were tested: 45% or 60% of calories from fat (Research Diets). The 45% HFD (D12451) contained 45% of calories from fat, 35% from carbohydrate, and 20% from protein. The 60% HFD (D12492) contained 60% of calories from fat, 20% from carbohydrate, and 20% from protein. The 60% HFD was used in subsequent studies and was compared with a regular chow diet (Lab Diet, catalog 5001), which contained 13.5% of calories from fat, 58% from carbohydrate, and 28.5% from protein.

Hyperglycemic animal model on an immunodeficient background. NSG-Tg(lm2-HBEGF)6832)Ugfms/mice, referred to as NSG RIP-DTR mice, were developed by backcrossing the RIP-DTR transgene from a B6CBA-RIP-DTR stock provided by Pedro Herrera. The original B6CBA Tg(lm2-HBEGF)6832)Ugfms/mice were made by injecting the construct into B6CBA eggs. The transgene was backcrossed using a marker-assisted speed congenic method to the NOD.Cg-Prkdc scid Il2rgtm27(Sj)J (abbreviated as NOD-scid IL2rgtm27 or NSG) strain background. These NSG RIP-DTR mice express the human DTR driven by a RIP. The RIP-DTR transgene was then fixed to homozygosity and maintained as a homozygous line. Transgenic mice, with 2 autosomal copies of the RIP-DTR transgene (40), in which DTR expression is driven by the RIP, were backcrossed onto the NSG background (25) for more than 10 generations, resulting in the NSG-DTR mouse.

DT preparation and administration. DT (List Biological Laboratories Inc., catalog 150) was administered to NSG-DTR mice in a single, 300 μl i.p. injection of 0.5, 1.0, 2.5, 5.0, 10, or 25 ng total DT. Control NSG-DTR mice (PBS) were treated with an equal volume of 1× PBS (Sigma-Aldrich). All animals in a cohort (with human islets from the same human donor) were injected with DT or PBS on the same day. Stock solutions reconstituted with water were stored at −20°C, according to the manufacturer’s recommendations, and stock solution aliquots were diluted for each use.

S961 treatment. S961 reagent (44, 45) was provided by Laufe Schäffer (Novo Nordisk). S961 is a 43-aa peptide antagonist that induces many consequences of insulin resistance in rodents, including hyperglycemia, hyperinsulinemia, decreased hepatic glycogen storage, and decreased adipocyte triglyceride storage (44, 45). The affinity of S961 for the insulin receptor rivals that of insulin itself, and specificity of S961 for the insulin receptor, rather than the similar IGF receptor, exceeds that of insulin (44). Either S961 or 1× PBS was loaded into Alzet 2001 (20 nM) osmotic pumps. Pumps were implanted 2 weeks after human islet engraftment. Animals were sacrificed, and tissues were harvested at either 7 or 14 days after pump implantation.

Human and mouse islets. Human islets (n = 13 preparations, Supplemental Table 1) were obtained from islet isolation centers that are part of the Integrated Islet Distribution Network (http://iidp.coh.org/). Assessment of human islet function was performed by perfusion on the day of islet arrival, as previously described (35, 102). Sixty size-matched islets were perfused with 5.6 mM glucose, 16.7 mM glucose, and 16.7 mM glucose with 100 μM 3-isobutyl-1-methyl-xanthine (IBMX) (Sigma-Aldrich, catalog I5879-1G). Insulin secretion was normalized to IEQs (102). Mouse islets were isolated from 13- to 15-week-old NSG mice or C57BL/6J mice (Jackson Laboratory) as described (41).

Islet transplantation. NSG or NSG-DTR male mice, between 12 and 20 weeks of age, were used for transplantation (103). For the NSG-HFD model, each recipient mouse received 1,500 IEQ human islets, 140 islets isolated from NSG mice, or 200 islets from C57BL/6J mice transplanted under the kidney capsule. After 2 weeks engraftment, the mice were placed on an RD or a 60% HFD for 12 weeks. For the NSG-DTR model, each recipient mouse received 2,000 or 4,000 human islet IEQ. For the S961 model, each recipient mouse received 4,000 human islet IEQ or 200 islets from C57BL/6J mice. All data with human islets from all models were normalized to 2,000 transplanted IEQ.

Immunohistochemistry of pancreas and human and mouse grafts. Immunohistochemical studies were performed as described (33, 104, 105). Antibodies used in this study were as follows: guinea pig anti-human insulin (catalog 0564, DAKO), rabbit anti-human Ki67 (catalog ab15580, Abcam), rabbit anti-human PDX1 (from Christopher Wright, Vanderbilt University), rabbit anti-human NKX6.1 (β Cell Biology Consortium), mouse anti-human CD31, and rat anti-mouse PECAM (catalog 550389, catalog 550274, BD Biosciences — Pharmingen). Images were acquired with an Olympus BX41 fluorescence microscope or a confocal laser-scanning microscope (PDX1 and NKX6.1 stain).

Assessment of glucose tolerance, random blood glucose, serum insulin, triglyceride, cholesterol, and tissue insulin content. The i.p. glucose tolerance tests were performed after a 6-hour fast, as previously described (104). All measurements were taken at the same recurring time of day.
Serum human insulin was measured using a species-specific radioimmunoassay from Millipore (catalog RI-14K). Serum mouse insulin was calculated as the difference between total (mouse and rodent, cross-reactive with human) and human-specific insulin measurements. Total serum insulin, pancreatic insulin content, and graft insulin content were measured as previously described (105). Serum triglyceride and cholesterol levels were measured from 10 μl of plasma using commercially available kits (Raiĉhem, Cliniqa) as previously described (106).

Assessment of apoptosis, oxidative stress, and amyloid deposition. Apoptosis was assessed by TUNEL stain (catalog S7165, Millipore) according to the manufacturer’s instructions. DHE (catalog D7008, Sigma-Aldrich) was used to measure O₂⁻; in cryosections, as described (107, 108). The cryosections were washed 3 times by PBS, followed by DHE staining for 30 minutes. Fluorescence intensity of islet grafts was quantified using ImageJ software (107). To assess amyloid deposits, sections from human grafts were first stained with the insulin antibody and then incubated with 0.5% concentration Thioflavin S (catalog T-1892, Sigma-Aldrich) in PBS. Grafts were visualized, and the images were obtained using an Olympus BX41 fluorescence microscope. Thioflavin S and insulin-positive areas were then quantified with MetaMorph software.

qRT-PCR. Total RNA from human grafts and mouse islets was isolated using an RNAlater RNA Isolation Kit (catalog 1912, Ambion), as previously described (35). RNA bioanalysis and quality control and quantity assessment (QC/QA), assessed in the Vanderbilt Function Genomics Shared Resource (FGSR) core lab, showed a 28S/18S ratio greater than 1.2 and a RNA integrity number (RIN) greater than 8.2. Quantitative reverse-transcriptase PCR (qRT-PCR) was performed using the TaqMan probe-primer and reagents from Applied Biosystems as described (35). ACTB, TBP, and TFCF were used as endogenous control genes. Relative changes in mRNA expression were calculated by the comparative ΔCt method using the Applied Biosystems StepOnePlus System. Primers are listed in Supplemental Table 2.

Electron microscopy. Ultrastructure of β cells and vasculature were studied by transmission electron microscopy (41). Mouse pancreas and grafts were removed after perfusion and fixed in 2.5% gluteraldehyde in 0.1 M cacodylate buffer. Samples were subsequently imaged on the Philips/FEI Tecnai T12 microscope at various magnifications.

siRNA-mediated knockdown of NKX6.1 and MAFB in EndoC-JH1 cells. Knockdown of NKX6.1 and MAFB was accomplished 3 days prior to GSIS using the Dharmafect no. 1 reagent following the manufacturer’s protocol. Briefly, ON-TARGETplus Smartpool siRNA against human NKX6.1 (catalog L-020083-00), human MAFB (catalog L-009018-00; GE Dharmacon), and scrambled nontargeting siRNA (catalog D001810; GE Dharmacon) were introduced into 2 × 10⁶ EndoC-JH1 cells (71) in antibiotic-free media. Following an overnight incubation, the cells were grown in normal growth media for an additional 36 hours and then overnight in low-glucose medium (1.1 mM glucose, 2% BSA, 50 μM 2-mercaptoethanol, 10 mM nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, and penicillin-streptomycin at 100 units/ml). Cells were incubated for 1 hour in DMEM base medium supplemented with 5.5 mM glucose or 15.5 mM glucose. Secreted insulin was analyzed from culture medium and was normalized to the insulin content following cell lysis (cell lysis buffer: 1 M Tris, Triton X-100, glycerol, 5 M NaCl, 0.2 M EGTA, protease inhibitor tablet). Insulin levels were analyzed by the Vanderbilt Hormone Assay Core. To assess silencing effects of NKX6.1 and MAFB, qRT-PCR was performed using TaqMan primers.

Statistics. Results are shown as mean ± SEM. Two-tailed Student’s t test or 1-way ANOVA was used for analysis of statistical significance. ANOVAs were followed by Newman-Keuls multiple comparison tests. A P value of less than 0.05 was considered significant.

Study approval. Studies with human islets were approved by the Vanderbilt Institutional Animal Care and Use Committee.

Author contributions
NSK, CD, RS, and ACP designed experiments and wrote the manuscript. CD, NSK, GP, AS, CT, RA, MS, and IGP performed experiments related to islet transplantation studies in NSG-DTR, NSG-HFD, and NSG-S961 models and characterization of the NSG-Glu4Δ⁻/⁻ and NSG-oh/o6 models. CE and JMS performed lipid quantification experiments. HAC and RS performed human cell line experiments. LDS, DLG, and PLH backcrossed the B6;CBA-RIP-DTR stock onto the NSG background, generating NSG-DTR mice, and edited the manuscript.

Acknowledgments
We thank Janice Williams for her expertise in acquiring electron microscopy images. This work was supported by grants from the Department of Veterans Affairs (BX000666, BX002223), the National Institute of Diabetes and Digestive and Kidney Diseases (DK68854, DK66636, DK69603, DK63439, DK62641, DK72473, DK89572, DK89538, DK68764, DK92758, DK97829, DK94199, DK104211, DK050203, DK095070, DK89572, DK104218, DK106755, DK104211, DK108120), JDRF, the Vanderbilt Diabetes Research and Training Center (DK20593), and the Helmsley Charitable Trust (2012PG-T1D018 and 2015PG-T1D057). The EndoC-JH1 cell line was provided by Raphael Scharffmann and Philippe Ravassard and the S961 was provided by Lauge Schäffer. N.S. Kayton was supported by a Vanderbilt Molecular Endocrinology Training Program grant (5T32 DK07563).

Address correspondence to: Alvin C. Powers, Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University School of Medicine, 7465 Medical Research Building IV, 2215 Garland Avenue, Nashville, Tennessee 37232-0475, USA. Phone: 615.936.7678; E-mail al.powers@vanderbilt.edu.


Exp. 1997;46(9):1044–1051.